AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00672932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: 400 mg two times daily for three months
Study NCT04586907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537021
Description: Administered SC.
Study NCT04586907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT01972113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Control
Description: one placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
Study NCT01972113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)
Description: one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
Study NCT01972113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
Description: one 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
Study NCT04005911 — intervention group
Intervention type: DEVICE
Intervention: Themography
Description: Using a FLIR camera, a thermographic recording will be taken of the patient while breathing. Simultaneously, the research investigator will record the thoracic impedance-based respiratory rate as well as manually count respirations in one minute.
Study NCT03861195 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic surgery
Description: patients affected by uterine diseases that undergo treatment
Study NCT03162055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium/Formoterol Fumarate
Description: Metered dose inhaler (MDI), contains glycopyrronium/formoterol fumarate fixed-dose combination 7.2/4.8 μg per actuation
Study NCT03162055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: umeclidinium/vilanterol
Description: Dry powder inhaler (DPI), Each metered dose contains umeclidinium/vilanterol 62.5/ 25μg fixed-dose combination per inhalation
Study NCT01011452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
Study NCT00836329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Glucose Management
Description: Participants in the intensive glucose management group will undergo strict management of their blood glucose levels with a target whole blood glucose level of 100-140 mg/dL preoperatively, intraoperatively, and postoperatively in the intensive care unit (ICU). Once meals are started, targets for glycemia management will be (a) fasting: 80-140 mg/dL, (b) postprandial: 140-180 mg/dL. Prior to hospital discharge, participants will receive an in-depth diabetes education session. After hospital discharge, participants will attend monthly study visits for 6 months so that study researchers can monitor their glycemia management.
Study NCT00836329 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Glucose Management:
Description: Participants will receive traditional management of blood glucose levels while in the hospital. They may receive insulin several times a day, based on the results of glucose monitoring.
Study NCT00326287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole medocaril
Study NCT00326287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone with or without Linezolid
Study NCT01011452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
Study NCT02915107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom
Description: PCI with BioFreedom
Study NCT02915107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orsiro
Description: PCI with BioFreedom
Study NCT01295580 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ARTZ
Description: Hyaluronic acid (five 2.5 mL injections)
Study NCT01350297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reinnervation
Description: anastomosis between right inferior laryngeal nerve and right phrenic nerve
Study NCT01423318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab
Description: Dose-level cohorts receiving single subcutaneous dose
Study NCT01295580 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DUROLANE
Description: Hyaluronic acid stabilized (one 3.0 mL injection + four weekly 0 mL sham injections)
Study NCT04419818 — intervention group
Intervention type: BEHAVIORAL
Intervention: Virtual Reality
Description: Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Participants will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action.
Study NCT03520725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: This gruop did not have an intervention
Study NCT03706690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] until clinical progression/ deterioration or confirmed radiological progression.
Study NCT03520725 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pineapple snack bar
Description: 30 g daily of pineapple snack bar
Study NCT03520725 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mango snack bar
Description: 30 g daily of mango snack bar
Study NCT03204760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8Mg Solution for Injection
Description: Effect single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg) in the treatment of mild to moderate acute asthma exacerbations in children
Study NCT03204760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Oral, Per 5 Mg
Description: Effect of prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses in the treatment of mild to moderate acute asthma exacerbations in children.
Study NCT02053844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lottery for tool users to win a $500 prize
Description: Intervention group is eligible to enter a monthly lottery to win a $500 gift card if they use the tool each month.
Study NCT02053844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced promotion of the tool to employers and members
Description: Intervention group also receives extra promotion of the tool through mailings, employer outreach, and automated phone calls
Study NCT01056614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT01423318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose subcutaneously
Study NCT00626223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-MTHF (5-methyltetrahydrofolate)
Description: 50 mg intravenous at the end of each hemodialysis session
Study NCT00626223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Description: 5 mg per day of oral folic acid
Study NCT02179489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC
Description: HIPEC with MMC: Mitomycin C (MMC) (30 mg/m2 of body surface area). Closed technique, as preferred. Duration: 60 minutes. Mean Intra-abdominal Temperature: 43°C.
Study NCT00780052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: c-myb AS ODN
Description: Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD.
Study NCT04309669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOT'HEMA
Description: three ampoules per day during 12 weeks
Study NCT04306055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire with precaution information
Description: Ever blood donors in this group would receive a questionnaire which includes some information about how donors can donate safely and how blood center will protect the blood donors during the epidemic of COVID-19.
Study NCT04306055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Questionnaire without precaution information
Description: Ever blood donors in this group would receive a questionnaire which dose not include the information above.
Study NCT01086046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low molecular weight heparin
Description: Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days.
Study NCT01086046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days.
Study NCT02160886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: child-goal
Description: The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks.~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions.
Study NCT02160886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent-goal
Description: The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks. .~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions.
Study NCT02396342 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV5-hFIX
Description: AAV5hFIX gene therapy
Study NCT00892957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)
Description: The actual dose of FS VH S/D 500 s-apr will depend on the length of the suture line and the intensity of bleeding (but shall not exceed 4 mL FS VH S/D 500 s-apr).
Study NCT00892957 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical gauze pads
Description: Manual compression with surgical gauze pads
Study NCT04144075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion Program
Description: It is a protocolized training program in mindfulness and self-compassion skills. It has a duration of 8 weekly group sessions of about two hours and 45 minutes and a silent retreat of 4 hours.
Study NCT04144075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behaviour Therapy Group
Description: It is a control intervention designed for the development of a control group suitable for comparison with experimental groups.
Study NCT04144075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: It is variable according to the clinical and personal characteristics of the patient, the most common components will be described.
Study NCT03184857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open maxillary sinus lifting
Description: biopsy of the region 6 months later
Study NCT03184857 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open maxillary sinus lifting
Description: biopsy of the region 6 months later
Study NCT01920321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic lung volume reduction
Description: Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.
Study NCT01404858 — intervention group
Intervention type: BEHAVIORAL
Intervention: There is no intervention; this is a survey only study
Description: There is no intervention; this is a survey only study
Study NCT03227965 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Immune cells population assesment
Description: T lymphocytes population description through blood, urine and faeces samples
Study NCT00086944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00086944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00086944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00086944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00086944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00086944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT01056614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT00086944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given SC
Study NCT00086944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01791699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxonidine
Study NCT01791699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03823092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: polarization sensitivity
Description: test of polarization vision as described in Study Description
Study NCT00213980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: 4 mg IV over 15 minutes administered once every 12 weeks times 4
Study NCT02119234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone/formoterol/glycopyrrolate
Study NCT02119234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone/formoterol/glycopyrrolate
Study NCT02119234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03418051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade II anterior to posterior ankle joint mobilizations with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
Study NCT03418051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
Study NCT01064076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S-ICD System
Description: The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
Study NCT01134757 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: house dust mite and alternaria allergen bronchial challenge
Description: 2 ml of saline-dissolved lyophylised house dust mite or alternaria in concentration 5000 standard biological units (SBU/ml) The challenge is the only intervention. dosed in 6 steps of 5, 10, 20, 40, 80, and 160 SBU. 10 minutes after each step up a spirometry will be performed the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
Study NCT04240171 — intervention group
Intervention type: DRUG
Intervention: Dapagliflozin 5Mg Tab
Description: Dapagliflozin 5mg tablets daily
Study NCT04240171 — intervention group
Intervention type: DRUG
Intervention: Glimepiride 4Mg Tab
Description: Glimepiride Tablets daily
Study NCT02687750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Investigational device is a dual tuned (fluorine/proton) MRI surface coil designed and produced by Clinical MR solutions
Study NCT02466412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHTP 1.1 M
Description: Single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M)
Study NCT01056614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study NCT01056614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV and orally
Study NCT03118570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: setrusumab
Description: Intravenous infusion
Study NCT02466412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mCC
Description: Single use of subject's own menthol conventional cigarette (mCC)
Study NCT03728712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SPECT/CT
Description: Technegas-Tc99m is approved by Health Canada for the evaluation of ventilation. Technegas will be prepared with a Technegas Generator (Cyclomedica) according to the manufacturer recommendations with a simmer phase and a burning phase. 95% ethanol will be used to wet the carbon crucible. The crucible will be loaded with 20-30 mCi of Tc99m. Tc99m has a physical half-life of 6 hours.~Technegas will be administered to the patient within 10 minutes of its preparation, in a separate room than the scanning room. The inhalation technique will be rehearsed with the patient prior to the actual inhalation. The patient will be in supine position. A mouth piece and a nose clip will be used. The patient will be instructed to take 3 breaths of Technegas, starting after normal exhalation. A survey meter will be used to monitor the quality of the inhalation.
Study NCT03118570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: tablets
Study NCT00673894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Glutamine 30g +sitagliptin 100mg
Study NCT00673894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glutamine 30g +placebo (matching sitagliptin 100 mg)
Study NCT03581929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Memormax
Description: Memormax is a food supplement indicated to support cognitive functions thanks to the Melissa officinalis; it also contains lyophilized Royal Jelly, Blueberry extract and Blueberry juice.
Study NCT03581929 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT02930616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patients in Group 1 will receive pCLE at first and WLE 2 months later
Study NCT03118570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: tablets
Study NCT01056614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT03706690 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression
Study NCT01390818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC1936369B (pimasertib)
Description: MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
Study NCT01056614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSC transplant
Study NCT01056614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSC transplant
Study NCT01056614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies